

6/4/02

101 Rec'd PCT/PTO 04 JUN 2002

20/04/98 68

Please type a plus sign (+) inside this box ➡

Approved for use through 10/31/2002. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/049,868
				Filing Date	February 11, 2002
				First Named Inventor	Hans Deckmyn and Nancy Cauwenberghs
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	522-1778
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	Maker Harold	Date Considered	10/21/04
-----------------------	--------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
		Application Number	10/049,868		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	February 11, 2002		
		First Named Inventor	Hans Deckmyn and Nancy Cauwenberghs		
		Group Art Unit	1644		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	522-1778

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MH	C1	Reverter, "Inhibition of Platelet - mediated, Tissue Factor induced...", J. Clin. Invest, vol a8, no. 3, 8/96, pp 863-874	
MH	C2	Pareti, "Interaction of porcine von Willebrand factor with the platelet....", British J. of Haematology, vol 82, 1992, pp 81 - 86	
MH	C3	Becker, "Effects of an Antiplatelet Glycoprotein Ib Antibody on...", Blood, vol 74, no.2, 8/1/89, pp 690-694	
MH	C4	Ward, "Epitope and functional characterization of the CD42...", Platelet antigens, pp 1336-1337	
MH	C5	Cowenberghs, "Antithrombotic Effect of Platelet Glycoprotein Ib- Blocking...", Arteriosclerosis, Thrombosis and Vascular Biology,	
MH	C6	Coller, "A Murine Monoclonal Antibody that Completely Blocks...", J. Clin. Invest. vol 72, 7/83, pp 325-338	
MH	C7	Shetler, "Antithrombotic Assessment of the Effects of Combination...", 1996, American Heart Association, pp 1719 - 1725	
MH	C8	Simoons, "Randomized Trial of a GPIIb/IIIa Platelet Receptor...", Circulation, vol 89, no2, 2/94, pp 596 - 603	
MH	C9	Schultz, "Use of C7E3 Fab in Conjunction With Primary Coronary...", Catheterization and Cardiovascular Diagnosis, vol 39, 1996, pp 143 - 148	
MH	C10	Lincoff, "Platelet Glycoprotein IIb/IIIa Receptor Blockade And ...", New England J. of Med., vol 336, no 24, 6/12/97, pp 1689-1697	
MH	C11	Gold, "Pharmacodynamic Study of F(ab)2 Fragments of ...", J. Clin. Invest., vol 86, 8/90, pp 651 - 659, 1990	

Examiner Signature	Maher Haddad	Date Considered	10/21/04
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

1

of

2

**Complete if Known**

Application Number

**Filing Date****First Named Inventor**

**Art Unit**

Examiner Name

Attorney Docket Number

**Hans Deckmyn**

1644

522-1778

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Maheer Haddad

Date	
Considered	

10/21/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/049868
		Filing Date	JC11 Rec'd PCT/PTO 11 FEB 2002
		First Named Inventor	Hans Deckmyn
		Group Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	522-1778	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		<del>Pareti, "Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex", British Journal of Haematology, vol 82, 1992, pp 81-86</del>	
		<del>Becker, "Effects of Antiplatelet Glycoprotein Ib Antibody on Hemostatic Function in the Guinea Pig", Blood, vol 74, No 2, 8/1/89, pp 690-694,</del>	
		<del>Ward, "Epitope and functional characterization of the CD42 (gplb/IX) mAb panel", Platelet antigens, pp 1336-1337</del>	
		<del>Cauwenberghs, "Antithrombotic Effect of Platelet Glycoprotein Ib - Blocking Monoclonal Antibody Fab Fragments in Nonhuman Primates", Arterioscler Thromb Vasc Biol., 1/4/2000, pp 1347-1353</del>	

Examiner Signature	Maher Haddad	Date Considered	10/21/04
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.